Beclomethasone at different doses for chronic asthma (review)

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Trials

Background:

• Beclomethasone dipropionate (BDP) is a widely used daily dose medication for managing long-term asthma.
• Understanding the dose-response relationship is crucial for optimizing asthma treatment.

Purpose of the Study:

• To evaluate the evidence supporting a dose-response relationship for Beclomethasone dipropionate in long-term asthma management.
• To determine if increasing BDP dosages yield significant clinical improvements.

Main Methods:

• Systematic review of prospective, randomized trials comparing different daily doses of BDP in patients over two years old with long-term asthma.
• Searched multiple databases and contacted study authors and manufacturers for eligible studies.
• Assessed trial quality and extracted data on efficacy and side effects.

Main Results:

• Eleven trials with 1614 subjects were included, showing variable methodological quality.
• Higher BDP doses (e.g., 800 mcg/d vs. 400 mcg/d) demonstrated small advantages in morning peak expiratory flow rate and FEV1 in non-oral steroid users.
• No significant differences were observed in daytime symptoms, exacerbations, side effects, or HPA axis function across different BDP doses.

Conclusions:

• Beclomethasone dipropionate exhibits a shallow dose-response effect in long-term asthma within the 400-1600 mcg/d range.
• The clinical relevance of observed improvements at higher doses is questionable.
• Further research may be needed to clarify the optimal BDP dosage for specific patient subgroups.